Table 2.
Factors associated with survival by univariate analysis.
| Factor | Overall survival | Progression-free survival | ||
|---|---|---|---|---|
| Hazard ratio (95% CI) | p | Hazard ratio (95% CI) | p | |
| Sex (male) | 1.16 (0.72–1.87) | 0.53 | 1.006 (0.66–1.53) | 0.98 |
| Age | 1.03 (1.006–1.056) | 0.02 | 1.019 (0.998–1.041) | 0.07 |
| PS 2–4 | 2.69 (1.66–4.35) | < 0.001 | 2.42 (1.57–3.72) | < 0.001 |
| B symptoms | 1.71 (1.022–2.86) | 0.04 | 1.55 (0.98–2.45) | 0.06 |
| Serum albumin | 0.41 (0.28–0.56) | < 0.001 | 0.49 (0.35–0.68) | < 0.001 |
| Elevated LDH (> ULN) | 2.10 (1.10–4.00) | 0.02 | 2.12 (1.42–4.81) | 0.002 |
| Ann-Arbor stage III-IV | 2.81 (1.53–5.15) | < 0.001 | 3.2 (1.83–5.6) | < 0.001 |
| Extranodal lesions | 2.24 (1.26–3.97) | 0.006 | 2.49 (1.48–4.19) | < 0.001 |
| Bulky lesion | 1.009 (0.54–1.88) | 0.98 | 0.96 (0.55–1.68) | 0.89 |
| IPI score | 1.50 (1.25–1.79) | < 0.001 | 1.53 (1.30–1.80) | < 0.001 |
| Diagnosed in other facilities | 1.15 (0.61–2.14) | 0.67 | 1.007 (0.57–1.79) | 0.98 |
| CHOP (vs dose-reduced) | 0.55 (0.34–0.89) | 0.02 | 0.80 (0.53–1.22) | 0.31 |
| Nonuse of rituximab | 3.76 (1.86–7.58) | < 0.001 | 2.95 (1.36–6.41) | 0.006 |
| Short DTI (0–22 days) | 2.89 (1.73–4.83) | < 0.001 | 2.64 (1.68–4.15) | < 0.001 |
PS performance status, LDH lactate dehydrogenase, ULN upper limit of normal, IPI International Prognostic Index, DTI diagnosis-to-treatment interval.